(Q46399401)

21 December 2017

title

One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease (English)

1 reference

21 December 2017

main subject

arterial hypertension

1 reference

A C Barreto

1

1 reference

21 December 2017

S M Franchi

series ordinal

2

1 reference

21 December 2017

C R P Castro

series ordinal

3

1 reference

21 December 2017

A A Lopes

series ordinal

4

1 reference

21 December 2017

language of work or name

English

0 references

publication date

15 February 2005

1 reference

21 December 2017

Brazilian Journal of Medical and Biological Research

published in

1 reference

21 December 2017

volume

38

1 reference

21 December 2017

issue

2

1 reference

21 December 2017

page(s)

185-195

1 reference

21 December 2017

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Treatment of pulmonary hypertension secondary to connective tissue diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Cyclic GMP phosphodiesterase-5: target of sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Sildenafil treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Sildenafil for primary and secondary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2005000200006

10.1590/S0100-879X2005000200006

21 January 2018

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017